Patients with statin resistance do not experience symptoms, Le noted. Instead, the problem is that statins do not lower LDL-C levels as much as they typically do. Instead of a 50% reduction, people ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Blumenthal said the ABC structure originated in the 1999 ...

A polypill that includes key medications associated with improved outcomes (aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as a simple approach to the secondary ...

A risk calculator that incorporates established cardiovascular risk factors and additional cardiac biomarkers, such as high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type ...

Objective: To apply the UK Medical Research Council (MRC) framework for development and evaluation of trials of complex interventions to a primary healthcare intervention to promote secondary ...

Both women and men with atherosclerotic cardiovascular disease (ASCVD) who take aspirin as secondary prevention fare just as well, for the most part, whether they’re on 81 mg or 325 mg daily, ...

Topline data show the Factor XIa inhibitor asundexian lowers recurrent stroke risk vs placebo with no increase in major bleeding events.

Once-daily asundexian 50 mg, on top of antiplatelet therapy, reduced risk for recurrent ischemic stroke after a ...

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management ...

Ultimately, investigators found a significant reduction in ischemic stroke risk with asundexian compared to placebo, both in combination with antiplatelet therapy. Additionally, participants had no ...